Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

Secondary Spinal Cord Injury llI: Pathophysiology

Secondary Spinal Cord Injury llI: Pathophysiology

Early Ischemia and Ionic ImbalanceWithin minutes of spinal cord injury, a secondary cascade begins, progressing over hours to weeks. Vascular damage reduces blood flow, causing ischemia and mitochondrial dysfunction. ATP depletion leads to ion pump failure, membrane depolarization, sodium influx, potassium efflux, and water accumulation, resulting in cellular swelling. Increased intracellular calcium further disrupts mitochondria and accelerates cellular injury.Excitotoxicity and Neuronal...

Neural Regulation

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Quantitative MRI findings indicate diffuse white matter damage in Susac Syndrome.

Multiple sclerosis journal - experimental, translational and clinical·2022

Same author

Diffusely abnormal white matter in clinically isolated syndrome is associated with parenchymal loss and elevated neurofilament levels.

Multiple sclerosis and related disorders·2021

Same author

Treatment of MOG antibody associated disorders: results of an international survey.

Journal of neurology·2020

Same author

Cannabis-based product use in a multiple sclerosis cohort.

Multiple sclerosis journal - experimental, translational and clinical·2019

Same author

FLAIR<sup>2</sup> improves LesionTOADS automatic segmentation of multiple sclerosis lesions in non-homogenized, multi-center, 2D clinical magnetic resonance images.

NeuroImage. Clinical·2019

Same author

Gadolinium Deposition in Deep Brain Structures: Relationship with Dose and Ionization of Linear Gadolinium-Based Contrast Agents.

AJNR. American journal of neuroradiology·2018

Search research articles

Related Experiment Video

Updated: Jun 16, 2026

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Does MRI lesion activity regress in secondary progressive multiple sclerosis?

Y Zhao¹, A J Petkau, A Traboulsee

¹MS/MRI Research Group, Department of Medicine, University of British Columbia, Vancouver, Canada. yinshan@msmri.medicine.ubc.ca

Multiple Sclerosis (Houndmills, Basingstoke, England)

|February 20, 2010

Summary

New contrast-enhancing lesions (CELs) in secondary progressive multiple sclerosis (SPMS) patients did not consistently decrease over time in placebo groups. Trends varied by cohort and initial lesion load.

More Related Videos

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

Related Experiment Videos

Last Updated: Jun 16, 2026

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

Area of Science:

Neuroscience
Radiology
Clinical Trials

Background:

Contrast-enhancing lesions (CELs) on MRI scans indicate active inflammation in multiple sclerosis (MS).
A previous study showed decreasing CEL rates in relapsing-remitting MS (RRMS) patients over 9 months.

Purpose of the Study:

To investigate the trend of new CELs in placebo-treated secondary progressive MS (SPMS) patients.
To determine if the phenomenon observed in RRMS patients applies to SPMS patients.

Main Methods:

Analysis of monthly MRI scans from two cohorts of placebo-treated SPMS patients (Cohort-1: 9 months, Cohort-2: 6 months).
Categorization of patients based on initial CEL count (0, 1-3, >3) and history of pre-study relapses.
Examination of monthly new CEL rates across different subgroups.

Main Results:

Cohort-1 showed no significant change in monthly new CEL rates, irrespective of initial CEL levels.
Cohort-2 exhibited a 33% decrease in monthly new CEL rates from months 1-3 to 4-6 in patients with 1-3 or >3 initial CELs.
A decreasing CEL rate was observed in a small subgroup (12 patients) with >3 initial CELs and pre-study relapses across combined cohorts.

Conclusions:

The short-term trend of new CEL activity in placebo-treated SPMS patients is variable and may differ between patient cohorts.
Initial lesion load and relapse history might influence the observed CEL activity trends in SPMS.